India, Sept. 25 -- Friday, CDT Equity Inc. (CDT), a data-driven biopharmaceutical company, announced that the Board has approved a 1-for-25 reverse stock split of the company's common stock to ensure continued compliance with the Nasdaq bid-price rule.
On the Nasdaq in the pre-market hours, the shares were trading 27.27 percent down at $0.0880, after closing Thursday's trading 10.30 percent lower.
The 1-for-25 reverse stock split will take effect on September 28, 2026. The company's common stock is expected to begin trading on a split-adjusted basis on Nasdaq at market open on September 29 under the existing ticker symbol 'CDT.'
Every 25 shares will be combined into one share, while the par value will remain $0.0001 per share, the compan...